ALX Oncology Holdings Inc. (ALXO) Stock Score, Valuation & Financial Research

ALX Oncology Holdings Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ALXO

ALX Oncology Holdings Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.39. These figures are a research snapshot, not a buy or sell recommendation.

What ALX Oncology Holdings Inc. does

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

ALX Oncology is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and potential future licensing or collaboration agreements to fund the research and development of its pipeline of novel cancer immunotherapies.

Products and services

  • The company is developing a pipeline of cancer therapies, primarily focusing on evorpacept, a CD47 blocker, and ALX2004, a novel EGFR-targeted antibody-drug conjugate.

Customer types

Clinical trial participants and healthcare providers.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials and drug candidates; specific supplier names are not disclosed. Source

Competitors and product-market comparisons

  • Companies developing CD47 blockers — The company faces competition from other entities developing CD47-targeting therapies, particularly those incorporating an active antibody Fc region. Source

Business strengths to evaluate

  • Differentiated mechanism of action for CD47 blocking Source

Business risks and research considerations

  • Dependence on clinical trial success and regulatory approval Source
  • Reliance on third-party manufacturers Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ALXO financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.39
Market capitalization:
187.04M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -80.89M
Free cash flow:
USD -84.35M
Cash:
USD 22.69M
Total debt:
USD 9.71M
EPS:
USD -1.13

What stands out

  • Free cash flow is USD -84.35M, negative for the stored period.
  • The balance sheet shows USD 22.69M of cash versus USD 9.71M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 12.98M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ALXO

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ALXO fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ALXO likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ALXO to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of ALXO's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ALXO

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.